Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anakinra + disease-modifying antirheumatic drugs
- Development stage
- Unknown
- Lead developer
- Sobi
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Anakinra + disease-modifying antirheumatic drugs (DMARDs) refers to the concurrent use of anakinra, a recombinant human interleukin-1 receptor antagonist, with one or more DMARDs (excluding TNF blocking agents) for the treatment of moderately to severely active rheumatoid arthritis and other inflammatory diseases in adults who have failed previous DMARD therapy. Anakinra acts by competitively inhibiting IL-1 binding to its receptor, thereby decreasing inflammation and preventing joint damage. This combination is designed to enhance therapeutic efficacy, but direct evidence for increased benefit is limited, and combination with TNF-blockers (e.g., etanercept, infliximab) is contraindicated due to higher risk of serious infections[2][3][4][6].
- Other names
- IL-1 receptor antagonistIL1 receptor antagonistIL 1 receptor antagonist
02
Targets
IL1R1 (Interleukin-1 Receptor Type 1)
Beyond the preview
Go deeper on anakinra + disease-modifying antirheumatic drugs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anakinra + disease-modifying antirheumatic drugs.